Page 18 - Viral Vector News Today

Viral Vector Market is Flourishing Globally, Key Players -BioReliance Richter-Helm UniQure

Nkarta and Sana Biotechnology have each leased space in California to support their cell therapy manufacturing plans.

In the three months since Johnson & Johnson's COVID-19 vaccine received emergency use authorization from the U.S. Food and Drug Administration, more than 10 million Americans have received the vaccine, according to the Centers for Disease Control and Prevention.

Viral Vector & Plasmid DNA Manufacturing Market Research Report by Type (Adeno-Associated Virus, Adenovirus, and Lentivirus), by Indication (Cancer, Genetic Disorder, and Infectious Disease), by Workflow, by Application, by End User, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19New York, June 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Viral Vector & Plasmid...

Major players in the gene therapy market are Novartis AG, Bluebird Bio, Inc. , Spark Therapeutics, Inc. , Audentes Therapeutics, Voyager Therapeutics, Applied Genetic Technologies Corporation, UniQure N.New York, June 09, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Gene Therapy Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06090625/?utm_source=GNW V., Celgene Corporation, Cellectis S.A., and Sangamo The...

Raw materials play a vital role in the development of cell and gene (CGT) therapies.

What are some of dos and don’ts on starter materials for CGT manufacturing? Raw materials play a vital role in the development of cell and gene (CGT) therapies. Mike Brewer, director, global principal consultant, regulatory, bioproduction, Thermo Fisher Scientific, spoke to BioPharma-Reporter about some of dos and don’ts on starter materials for CGT manufacturing. His advice is particularly targeted at newer entrants to the CGT space, those at the at the preclin...

Researchers at Children's Hospital of Philadelphia (CHOP) have developed a proof-of-concept treatment for blood disorders like sickle cell disease and beta-thalassemia that could raise hemoglobin levels by activating production of both fetal and adult hemoglobin.

Viral Vector & Plasmid DNA Manufacturing Market is expected to reach US$ 2,247.7 Mn by 2027 with Brammer Bio, Sanofi, Cardinal Health Inc., FUJIFILM Diosyn

INTRODUCTION Over the past few years, a number of advanced therapy medicinal products, including cell and gene therapies, have been developed and approved for the treatment of a variety of disease indications.New York, May 28, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, and Geographical Regions : Industry Trends ...